Background:
β-thalassemia
is
an
autosomal
recessive
hereditary
hemoglobin
production
disorder
characterized
by
abnormal
synthesis.
The
efficient
and
safe
therapies
for
transfusion-dependent
(TDT)
patients
are
desperately
required
to
minimize
the
requirement
blood
transfusion.
Objective:
To
establish
safety
efficacy
of
low-dose
thalidomide
in
TDT
patients.
Methodology:
retrospective
cohort
study
was
conducted
Khyber
Medical
University,
Peshawar
Blood
Diseases
Clinic,
investigate
therapy
Samples
were
collected
from
diagnosed
cases
whose
ages
≥3
years
on
treatment
a
period
≥6
months.
Complete
count
CBC
performed
Sysmex
XP-100,
Japan
biochemical
tests
Cobas
6000
analyzer
series.
Comprehensive
patients’
demographics,
clinical
history
prognosis
data
recorded
analyzed
using
SPPS
27.
Results:
patient
characteristics,
parameters
hematological
response
assessed
statistically
tested
384
therapy.
Applying
criteria
Hb
level
achievement,
we
marked
significant
results
(<0.001)
Excellent,
Good,
Partial
responders
that
184
(47.9%),
96
(25%),
60
(15.6%),
respectively.
common
side
effects
observed
with
drug
included
abdominal
discomfort,
nausea,
vomiting,
headache,
constipation,
dizziness,
fatigue,
anxiety,
repeated
infections,
skin
rash,
controlled
symptomatic
and/or
dose
adjustment.
Conclusion:
Collectively,
effective
increasing
levels
thus
reducing
requirements
transfusion
Future
trials
suggested
strengthen
guidelines
its
rational
use
Cancer Letters,
Год журнала:
2023,
Номер
560, С. 216125 - 216125
Опубликована: Март 12, 2023
Beyond
its
use
as
an
antiepileptic
drug,
over
time
valproate
has
been
increasingly
used
for
several
other
therapeutic
applications.
Among
these,
the
antineoplastic
effects
of
have
assessed
in
vitro
and
vivo
preclinical
studies,
suggesting
that
this
agent
significantly
inhibits
cancer
cell
proliferation
by
modulating
multiple
signaling
pathways.
During
last
years
various
clinical
trials
tried
to
find
out
if
co-administration
could
enhance
activity
chemotherapy
glioblastoma
patients
suffering
from
brain
metastases,
demonstrating
inclusion
schedule
causes
improved
median
overall
survival
some
but
not
others.
Thus,
concomitant
are
still
controversial.
Similarly,
lithium
tested
anticancer
drug
studies
mainly
using
unregistered
formulation
chloride
salts.
Although,
there
no
data
showing
superimposable
registered
carbonate,
shown
hepatocellular
cancers.
However,
few
interesting
performed
with
carbonate
on
a
very
small
number
patients.
Based
published
data,
represent
potential
complementary
approach
standard
chemotherapy.
Same
advantageous
characteristics
less
convincing
carbonate.
Therefore,
planning
specific
phase
III
is
necessary
validate
repositioning
these
drugs
present
future
oncological
research.
Clinical Pharmacology & Therapeutics,
Год журнала:
2023,
Номер
unknown
Опубликована: Сен. 26, 2023
The
emergence
of
chimeric
antigen
receptor
(CAR)
T-cell
therapy
has
revolutionized
the
treatment
hematologic
malignancies,
including
multiple
myeloma
(MM).
Two
BCMA-directed
CAR
products
-
idecabtagene
vicleucel
(ide-cel)
and
ciltacabtagene
autoleucel
(cilta-cel)
have
received
US
Food
Drug
Administration
(FDA)
approval
for
patients
with
relapsed/refractory
MM
who
underwent
four
or
more
prior
lines
(including
an
immunomodulatory
agent,
a
proteasome
inhibitor,
anti-CD38
monoclonal
antibody).
Despite
producing
unprecedented
response
rates
in
otherwise
difficult
to
treat
patient
population,
therapies
are
commonly
associated
immune-related
adverse
events
(e.g.,
cytokine
release
syndrome
neurotoxicity),
cytopenias,
infections.
Moreover,
many
continue
exhibit
relapse
post-treatment,
resistance
mechanisms
yet
be
fully
understood.
Ongoing
basic,
translational,
clinical
research
efforts
poised
generate
deeper
insights
into
optimal
utilization
these
therapies,
improve
their
efficacy,
minimize
toxicity,
identify
new
target
antigens
MM.
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Сен. 2, 2024
Objective
This
project
aims
to
identify
the
top
30
drugs
most
commonly
associated
with
constipation
and
their
signal
values
within
FDA
Adverse
Event
Reporting
System
database.
Methods
We
extracted
adverse
drug
events
(ADEs)
related
from
FAERS
database
spanning
January
1,
2004,
September
30,
2023.
compiled
frequently
reported
based
on
frequency
of
events.
employed
detection
methodologies
ascertain
whether
these
elicited
significant
signals,
including
reporting
odds
ratio,
proportional
multi-item
gamma
Poisson
shrinker,
information
component
given
by
Bayesian
confidence
propagation
neural
network.
Furthermore,
we
conducted
a
time-to-onset
(TTO)
analysis
for
generating
signals
using
medians,
quartiles,
Weibull
shape
parameter
test.
Results
total
50,
659,
288
ADEs,
among
which
169,897
(0.34%)
were
constipation.
selected
ranked
drugs.
The
highest
ranking
was
lenalidomide
(7,730
cases,
4.55%),
prevalent
class
being
antineoplastic
immunomodulating
agents.
Signal
performed
drugs,
risk
identified
26
them.
Among
22
exhibited
consistent
those
listed
FDA-approved
labels.
However,
four
(orlistat,
nintedanib,
palbociclib,
dimethyl
fumarate)
presented
an
unexpected
Ranked
values,
sevelamer
carbonate
emerged
as
strongest
[reporting
ratio
(95%
CI):
115.51
(110.14,
121.15);
PRR
(χ
2
):
83.78
(191,709.73);
EBGM
(EB05):
82.63
(79.4);
IC
(IC025):
6.37
(4.70)].
A
TTO
that
generated
revealing
all
early
failure
type.
median
orlistat
3
days,
shortest
while
clozapine
1,065
longest
Conclusion
Our
study
provides
list
potentially
drug-induced
(DIC).
could
inform
clinicians
about
some
alternative
medications
consider
when
managing
secondary
causes
or
caring
patients
prone
DIC,
thereby
reducing
incidence
mortality
DIC.
